Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733341 | 0.88 | KDM1A (0.35) | KDM1A | |
| SCHEMBL731436 | 0.86 | KDM1A (0.35) | KDM1A | |
| SCHEMBL731027 | 0.85 | KDM1A (0.32) | KDM1A | |
| SCHEMBL4045639 | 0.84 | KDM1A (0.34) | KDM1A | |
| SCHEMBL731360 | 0.79 | DRD2 (0.33) | KDM1A | |
| SCHEMBL731222 | 0.75 | PGR (0.43) | KDM1ABACE1 | |
| SCHEMBL733454 | 0.75 | KDM1A (0.39) | KDM1ABACE1 | |
| SCHEMBL731890 | 0.75 | KDM1A (0.35) | KDM1A | |
| SCHEMBL4445905 | 0.74 | KDM1A (0.34) | KDM1A | |
| SCHEMBL731083 | 0.73 | DRD2 (0.33) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138179-B2 | Spiro-imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-20090192145-A1 | Spiro-Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| EP-2010540-A1 | SPIRO-IMIDAZO COMPOUNDS | Speedel Experimenta AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007116098-A1 | SPIRO-IMIDAZO COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192145-A1 | Spiro-Imidazo Compounds | REN, NR3C2, AGTR1 | KDM1A 3697/4885BACE1 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.